Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 16/20 | 0.71 |
| ▸ | THRB | P10828 | 16/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900331 | 0.81 | FFAR1 (0.67) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4896456 | 0.80 | THRA (0.77) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4809771 | 0.80 | PTPRA (0.58) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4890146 | 0.79 | THRA (0.74) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4887009 | 0.78 | THRA (0.75) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4892311 | 0.77 | THRA (1.00) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4897754 | 0.77 | THRA (0.76) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4896380 | 0.77 | THRB (0.73) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL5072110 | 0.76 | THRA (0.81) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL4898980 | 0.76 | THRA (1.00) | THRATHRBESR1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRA 559/4885THRB 792/4885ESR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.